ArticleTransboundary and emerging diseases2025
Development of a Competitive ELISA for Detecting Antibodies Against Pseudorabies Virus Glycoprotein D.
Article in Transboundary and emerging diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A Humanized Anti-gD Broadly Neutralizing Antibody Confers Complete Post-Exposure Protection Against Pseudorabies Virus.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Development and characterization of a monoclonal antibody against Pseudorabies virus glycoprotein B and its application in tracking viral infection.Frontiers in microbiology · 2026Article
- Innovations, Applications, and Future Trends in Veterinary Diagnostic Technologies.Transboundary and emerging diseases · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pseudorabies virus (PRV) causes substantial economic losses in the global swine industry. Serological diagnosis plays a crucial role in its eradication. Here, we developed a competitive enzyme-linked immunosorbent assay (cELISA) to detect antibodies against PRV glycoprotein D (gD). First, the recombinant gD ectodomain was expressed and purified to immunize mice, resulting in the generation of a monoclonal antibody (mAb 1D11) that targets gD. Subsequently, this antibody was conjugated with horseradish peroxidase (HRP), serving as the competing reagent. The cELISA was optimized under ideal conditions. Furthermore, validation using 204 swine serum samples-comprising 110 PRV-positive and 94 PRV-negative samples-demonstrated a high sensitivity and specificity, with a cutoff value of 46.16% inhibition determined by receiver operating characteristic (ROC) analysis (area under the curve = 0.995). Importantly, no cross-reactivity was observed with antibodies against other tested swine viruses. Both intra- and inter-assay coefficients of variation were found to be less than 10%, confirming high reproducibility of the assay results. When compared to a commercial PRV glycoprotein B (gB) ELISA kit (IDEXX), our cELISA exhibited strong agreement with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.